Maura Francesco, Cutrona Giovanna, Mosca Laura, Matis Serena, Lionetti Marta, Fabris Sonia, Agnelli Luca, Colombo Monica, Massucco Carlotta, Ferracin Manuela, Zagatti Barbara, Reverberi Daniele, Gentile Massimo, Recchia Anna Grazia, Bossio Sabrina, Rossi Davide, Gaidano Gianluca, Molica Stefano, Cortelezzi Agostino, Di Raimondo Francesco, Negrini Massimo, Tassone Pierfrancesco, Morabito Fortunato, Ferrarini Manlio, Neri Antonino
a Department of Clinical Sciences and Community Health , University of Milano and Hematology 1 CTMO, Foundation IRCCS Ca' Granda, Ospedale Maggiore Policlinico , Milano , Italy.
b SS Molecular Diagnostics, IRCCS S. Martino-IST , Genova , Italy.
Leuk Lymphoma. 2015;56(11):3150-8. doi: 10.3109/10428194.2015.1028051. Epub 2015 May 18.
In this study we investigated specific biological and clinical features associated with chronic lymphocytic leukemia (CLL) patients carrying stereotyped BCR subset #4 (IGHV4-34) among a prospective cohort of 462 CLL/MBL patients in early stage (Binet A). All subset #4 patients (n = 16) were characterized by the IGHV mutated gene configuration, and absence of unfavorable cytogenetic lesions, NOTCH1 or SF3B1 mutations. Gene and miRNA expression profiling evidenced that the leukemic cells of subset #4 cases showed significant downregulation of WDFY4, MF2A and upregulation of PDGFA, FGFR1 and TFEC gene transcripts, as well as the upregulation of miR-497 and miR-29c. The transfection of miR-497 mimic in primary leukemic CLL cells induced a downregulation of BCL2, a known validated target of this miRNA. Our data identify biological characteristics associated with subset #4 patients, providing further evidence for the putative role of BCR in shaping the features of the tumor cells in CLL.
在本研究中,我们在一个由462例早期(Binet A期)慢性淋巴细胞白血病(CLL)/单克隆B淋巴细胞增多症(MBL)患者组成的前瞻性队列中,调查了携带定型BCR亚群#4(IGHV4-34)的CLL患者的特定生物学和临床特征。所有亚群#4患者(n = 16)的特征为IGHV基因呈突变型构型,且不存在不良细胞遗传学病变、NOTCH1或SF3B1突变。基因和miRNA表达谱分析表明,亚群#4病例的白血病细胞显示WDFY4、MF2A显著下调,PDGFA、FGFR1和TFEC基因转录本上调,以及miR-497和miR-29c上调。在原发性白血病CLL细胞中转染miR-497模拟物可诱导BCL2下调,BCL2是该miRNA的一个已知有效靶点。我们的数据确定了与亚群#4患者相关的生物学特征,为BCR在塑造CLL肿瘤细胞特征中的假定作用提供了进一步证据。